UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 420

Sortiert nach

Two Phase 3 Trials of Baricitinib for Alopecia Areata

The New England journal of medicine, 2022-05, Vol.386 (18), p.1687-1699

2022

Volltextzugriff (PDF)

Predicting disease genes based on multi-head attention fusion

BMC bioinformatics, 2023-04, Vol.24 (1), p.162-162, Article 162

2023

Volltextzugriff (PDF)

Investigation of Two-Dimensional Ultrasonic Surface Burnishing Process on 7075-T6 Aluminum

Chinese journal of mechanical engineering, 2021-12, Vol.34 (1), p.1-17, Article 19

English ed., 2021

Volltextzugriff (PDF)

Prediction and risk stratification from hospital discharge records based on Hierarchical sLDA

BMC medical informatics and decision making, 2022-01, Vol.22 (1), p.14-14, Article 14

2022

Volltextzugriff (PDF)

Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review

Dermatology and therapy, 2023-12, Vol.13 (12), p.2951-2991

2023

Volltextzugriff (PDF)

Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib

Dermatology and therapy, 2024-07, Vol.14 (7), p.1959-1968

2024

Volltextzugriff (PDF)

Mechanosensing of cells in 3D gel matrices based on natural and synthetic materials

Cell biology international, 2014-11, Vol.38 (11), p.1233-1243

2014

Volltextzugriff (PDF)

Terrestrial dissolved organic carbon consumption by heterotrophic bacterioplankton in the Huanghe River estuary during water and sediment regulation

Journal of oceanology and limnology, 2019-05, Vol.37 (3), p.1062-1070

2019

Volltextzugriff (PDF)

DDAffinity: predicting the changes in binding affinity of multiple point mutations using protein 3D structure

Bioinformatics (Oxford, England), 2024-06, Vol.40 (Supplement_1), p.i418-i427

2024

Volltextzugriff (PDF)

Matching within a hybrid RCT/RWD: framework on associated causal estimands

Journal of biopharmaceutical statistics, 2023-07, Vol.33 (4), p.439-451

2023

Volltextzugriff (PDF)

Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study

Journal of the American Academy of Dermatology, 2021-10, Vol.85 (4), p.847-853

2021

Volltextzugriff (PDF)

Power priors with entropy balancing weights in data augmentation of partially controlled randomized trials

Journal of biopharmaceutical statistics, 2022-01, Vol.32 (1), p.4-20

2022

Volltextzugriff (PDF)

52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB69-AB69

2024

Volltextzugriff (PDF)

49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB251-AB251

2024

Volltextzugriff (PDF)

52898 Among scalp non-responder patients with eyebrow/eyelash regrowth in the first year, continued treatment with baricitinib resulted in meaningful scalp responses for patients with severe alopecia areata

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB15-AB15

2024

Volltextzugriff (PDF)

P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2

British journal of dermatology (1951), 2023-06, Vol.188 (Supplement_4)

2023

Volltextzugriff (PDF)

41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB127-AB127

2023

Volltextzugriff (PDF)

Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)

American journal of clinical dermatology, 2023-05, Vol.24 (3), p.443-451

2023

Volltextzugriff (PDF)

Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies

Journal of the American Academy of Dermatology, 2024-06

2024

Volltextzugriff (PDF)

43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB69-AB69

2023

Volltextzugriff (PDF)

42146 Concurrent improvement in scalp hair and eyebrow or eyelash regrowth in patients with severe alopecia areata treated with baricitinib

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB29-AB29

2023

Volltextzugriff (PDF)

The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring

Journal of biopharmaceutical statistics, 2020-09, Vol.30 (5), p.882-899

2020

Volltextzugriff (PDF)

Regression analysis of mixed panel count data with dependent terminal events

Statistics in medicine, 2017-05, Vol.36 (10), p.1669-1680

2017

Volltextzugriff (PDF)

26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB85-AB85

2021

Volltextzugriff (PDF)

The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of right censoring

Journal of biopharmaceutical statistics, 2020-06, Vol.30 (5), p.882-899

2020

Volltextzugriff (PDF)

1 – 25 von 420

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(373)
Mit Volltextzugriff
(403)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(305)
Technology
(131)
Life Sciences & Biomedicine
(128)
Physical Sciences
(113)
Materials Science
(76)
Chemistry
(73)
Materials Science, Multidisciplinary
(63)
Engineering
(62)
Humans
(60)
Chemistry, Physical
(42)
Physics
(40)
Science & Technology - Other Topics
(36)
Animals
(33)
Physics, Applied
(27)
Female
(26)
Male
(21)
Oncology
(21)
Chemistry, Multidisciplinary
(20)
Engineering, Electrical & Electronic
(20)
Mice
(20)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Two Phase 3 Trials of Baricitinib for Alopecia Areata

Predicting disease genes based on multi-head attention fusion

Investigation of Two-Dimensional Ultrasonic Surface Burnishing Process on 7075-T6 Aluminum

Prediction and risk stratification from hospital discharge records based on Hierarchical sLDA

Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review

Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib

Mechanosensing of cells in 3D gel matrices based on natural and synthetic materials

Terrestrial dissolved organic carbon consumption by heterotrophic bacterioplankton in the Huanghe River estuary during water and sediment regulation

DDAffinity: predicting the changes in binding affinity of multiple point mutations using protein 3D structure

Matching within a hybrid RCT/RWD: framework on associated causal estimands

Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study

Power priors with entropy balancing weights in data augmentation of partially controlled randomized trials

52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials

49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2

52898 Among scalp non-responder patients with eyebrow/eyelash regrowth in the first year, continued treatment with baricitinib resulted in meaningful scalp responses for patients with severe alopecia areata

P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2

41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata

Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)

Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies

43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2

42146 Concurrent improvement in scalp hair and eyebrow or eyelash regrowth in patients with severe alopecia areata treated with baricitinib

The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring

Regression analysis of mixed panel count data with dependent terminal events

26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study

The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of right censoring

Suchergebnisse filtern